Omega Healthcare Investors (OHI) Earnings Analysis
Omega Healthcare Investors (OHI) next reports earnings on 2026-07-29, consensus EPS 0.509 USD. Last quarter (2026-02-04) it beat with EPS 0.55 USD vs 0.4952 USD est (+11.1%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 23.65.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does OHI next report earnings?
| Next earnings date | 2026-07-29 |
|---|---|
| Consensus EPS estimate | 0.509 USD |
| Revenue estimate | 0.27B |
OHI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-04 | 0.55 USD | 0.4952 USD | +11.1% | Beat |
| 2025-10-30 | 0.79 USD | 0.77 USD | +2.6% | Beat |
| 2025-07-31 | 0.77 USD | 0.75 USD | +2.7% | Beat |
| 2025-05-01 | 0.75 USD | 0.75 USD | 0% | Beat |
| 2025-02-05 | 0.74 USD | 0.41 USD | +80.5% | Beat |
| 2024-08-01 | 0.71 USD | 0.69 USD | +2.9% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
OHI valuation and analyst view
| Trailing P/E | 23.65 |
|---|---|
| Trailing EPS | 2.128 USD |
| Price / book | 2.90 |
| Dividend yield | 5.30% |
| Market cap | 15.06B |
| Analyst consensus | Hold (7 buy / 18 hold / 3 sell) |
| Avg price target | 50.29 USD |
Related research pages
Frequently asked questions
When is Omega Healthcare Investors (OHI)'s next earnings date?
Omega Healthcare Investors is next scheduled to report on 2026-07-29, with a consensus EPS estimate of 0.509 USD and revenue estimate of 0.27B.
Did OHI beat earnings last quarter?
In its 2026-02-04 report, OHI posted EPS of 0.55 USD versus a 0.4952 USD estimate — a beat of 11.1%.
What is OHI's earnings track record?
Over the last 6 reported quarters with consensus data, OHI beat estimates 6 times (100%).
What is OHI's current P/E ratio and EPS?
OHI trades at a trailing P/E of 23.65 on trailing EPS of 2.12790231848832 USD.
What do analysts rate OHI?
Analyst consensus is "Hold" across 28 ratings (0 strong buy, 7 buy, 18 hold, 3 sell, 0 strong sell). Average 12-month price target: 50.29 USD.